共 55 条
Identifying the differential effects of silymarin constituents on cell growth and cell cycle regulatory molecules in human prostate cancer cells
被引:57
作者:
Deep, Gagan
[1
]
Oberlies, Nicholas H.
[2
]
Kro, David J.
[2
]
Agarwal, Rajesh
[1
,3
]
机构:
[1] Univ Colorado, Sch Pharm, Dept Pharmaceut Sci, Denver, CO 80262 USA
[2] Res Triangle Inst, Ctr Organ & Med Chem, Natl Prod Lab, Res Triangle Pk, NC 27709 USA
[3] Univ Colorado, Ctr Canc, Denver, CO 80262 USA
关键词:
prostate cancer;
chemoprevention;
silymarin;
flavonolignans;
cell cycle;
D O I:
10.1002/ijc.23485
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Prostate cancer (PCa) is the leading cause of cancer-related deaths in men; urgent measures are warranted to lower this deadly malignancy. Silymarin is a known cancer chemopreventive agent, but the relative anticancer efficacy of its constituents is still unknown. Here, we compared the efficacy of 7 pure flavonolignan compounds isolated from silymarin, namely silybin A, silybin B, isosilybin A, isosilybin B, silydianin, isosilydianin, silychristin and isosilychristin, in advanced human PCa PC3 cells. Silybin A, silybin B, isosilybin A, isosilybin B, silibinin and silymarin strongly inhibited the colony formation by PC3 cells (p < 0.001), while silydianin, silychristin and isosilychristin had marginal effect (p < 0.05). Using cell growth and death assays, we identified isosilybin B as the most effective isomer. FACS analysis for cell cycle also showed that silybin A, silybin B, isosilybin A, isosilybin B, silibinin and silymarin treatment resulted in strong cell cycle arrest in PC3 cells after 72 hr of treatment, while the effect of silydianin, silychristin and isosilychristin was marginal (if any). Western blot analysis also showed the differential effect of these compounds on the levels of cell cycle regulators-cyclins (D, E, A and B), CDKs (Cdk2, 4 and Cdc2), CDKIs (p21. and p27) and other cell cycle regulators (Skp2, Cdc25A, B, C and Chk2). This study provided further evidence for differential anticancer potential among each silymarin constituent, which would have potential implications in devising better formulations of silymarin against prostate and other cancers. (C) 2008 Wiley-Liss, Inc.
引用
收藏
页码:41 / 50
页数:10
相关论文